Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.12 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: vodobatinib, bosutinib, ponatinib +12 | 1.00 |
| trials ClinicalTrials.gov | 9 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 29 Parkinson's papers of 26,043 | 0.55 |
| pathways Reactome | 9 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 2326
Sealed predictions
- BCR in dopamine neurons, braak+0.04 (p 0.928) → -0.37 (p 0.321)receipt 2331
Swarm cases
receipt 2331: BCR in dopamine neurons, braak
- power
- full sample -0.20 (p 0.429, n 18), 95% CI -0.61 to +0.30. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.19 (p 0.460, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.44 (p 0.069, n 18). could be the mix.
- skeptic
- leave-one-out range -0.29 to -0.10, sign flips 0; without severely affected donors -0.20 (p 0.429, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for BCR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts